Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer : The Kailuan Study
PURPOSE: The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated.
MATERIALS AND METHODS: Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or total cholesterol (TC) with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia, and normal FBG/non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model.
RESULTS: During 1,134,843.68 person-years follow-up, a total of 388 PLC cases occurred. We found the elevated FBG and hypocholesterolemia increase the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (hazard artio [HR], 1.19; 95% confidence interval [CI], 0.88 to 1.62) and hypocholesterolemia/normal FBG group (HR, 1.53; 95% CI, 1.19 to 1.97), and in the hypocholesterolemia/elevated FBG group (HR, 3.16; 95% CI, 2.13 to 4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease.
CONCLUSION: Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
---|---|
Enthalten in: |
Cancer research and treatment - 53(2021), 4 vom: 20. Okt., Seite 1113-1122 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ma, Xiangming [VerfasserIn] |
---|
Links: |
---|
Themen: |
97C5T2UQ7J |
---|
Anmerkungen: |
Date Completed 07.02.2022 Date Revised 27.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.4143/crt.2020.817 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM32056164X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM32056164X | ||
003 | DE-627 | ||
005 | 20231225173839.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.4143/crt.2020.817 |2 doi | |
028 | 5 | 2 | |a pubmed24n1068.xml |
035 | |a (DE-627)NLM32056164X | ||
035 | |a (NLM)33494124 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ma, Xiangming |e verfasserin |4 aut | |
245 | 1 | 0 | |a Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer |b The Kailuan Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.02.2022 | ||
500 | |a Date Revised 27.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a PURPOSE: The influence of fasting blood glucose (FBG) and cholesterolemia primary liver cancer (PLC) in china was analyzed via a large prospective cohort study based on a community population, and the combined effects between them were investigated | ||
520 | |a MATERIALS AND METHODS: Overall, 98,936 staff from the Kailuan Group who participated in and finished physical examinations between 2006 and 2007 were included in the cohort study. Their medical information was collected and they were followed up after examination. The correlations of serum FBG or total cholesterol (TC) with PLC were analyzed. Then, we categorized all staff into four groups: normal FBG/non-hypocholesterolemia, normal FBG/hypocholesterolemia, elevated FBG/non-hypocholesterolemia, elevated FBG/hypocholesterolemia, and normal FBG/non-hypocholesterolemia was used as a control group. The combined effects of elevated FBG and hypocholesterolemia with PLC were analyzed using the Age-scale Cox proportional hazard regression model | ||
520 | |a RESULTS: During 1,134,843.68 person-years follow-up, a total of 388 PLC cases occurred. We found the elevated FBG and hypocholesterolemia increase the risk for PLC, respectively. Compared with the non-hypocholesterolemia/normal FBG group, the risk of PLC was significantly increased in the non-hypocholesterolemia/elevated FBG group (hazard artio [HR], 1.19; 95% confidence interval [CI], 0.88 to 1.62) and hypocholesterolemia/normal FBG group (HR, 1.53; 95% CI, 1.19 to 1.97), and in the hypocholesterolemia/elevated FBG group (HR, 3.16; 95% CI, 2.13 to 4.69). And, a significant interaction effect was found of FBG and TC on PLC. All results were independent from the influence of liver disease | ||
520 | |a CONCLUSION: Elevated serum FBG and hypocholesterolemia are risk factors for PLC, especially when combined. Thus, for the prevention and treatment of PLC, serum FBG and TC levels should be investigated | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cholesterol | |
650 | 4 | |a Cohort studies | |
650 | 4 | |a Combined effect | |
650 | 4 | |a Glucose | |
650 | 4 | |a Liver neoplasms | |
650 | 7 | |a Blood Glucose |2 NLM | |
650 | 7 | |a Cholesterol |2 NLM | |
650 | 7 | |a 97C5T2UQ7J |2 NLM | |
700 | 1 | |a Cui, Haozhe |e verfasserin |4 aut | |
700 | 1 | |a Sun, Miaomiao |e verfasserin |4 aut | |
700 | 1 | |a Liu, Qian |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xining |e verfasserin |4 aut | |
700 | 1 | |a Li, Guangjian |e verfasserin |4 aut | |
700 | 1 | |a Wei, Yaochen |e verfasserin |4 aut | |
700 | 1 | |a Fu, Qingjiang |e verfasserin |4 aut | |
700 | 1 | |a Liu, Siqing |e verfasserin |4 aut | |
700 | 1 | |a Cao, Liying |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer research and treatment |d 2001 |g 53(2021), 4 vom: 20. Okt., Seite 1113-1122 |w (DE-627)NLM190743158 |x 2005-9256 |7 nnns |
773 | 1 | 8 | |g volume:53 |g year:2021 |g number:4 |g day:20 |g month:10 |g pages:1113-1122 |
856 | 4 | 0 | |u http://dx.doi.org/10.4143/crt.2020.817 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 53 |j 2021 |e 4 |b 20 |c 10 |h 1113-1122 |